Key Market Indicator:
F&G: 40
25.289,84 NASDAQ · 48.612,00 DOW · 6.895,60 S&P · 4.295,56 Gold · 60,71 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE000A3ENQ51
Filter zurücksetzen
© EQS Newswire
11.12.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma delivers on full-year revenue and profitability targets
Article
News Preview
SCHOTT Pharma delivers on full-year revenue and profitability targets Revenue of EUR 986.2m reflects a 5.8% growth at constant currencies EBITDA margin at constant currencies increased to 28.4% (prior year: 26.9%) Successful expansion of high-value solutions (HVS) – revenue share increased to 57% (prior year: 55%) Guidance for FY 2026: 2-5% rev......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität
Article
News Preview
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität Währungsbereinigtes Umsatzwachstum von 5,8 % auf 986,2 Mio. EUR Währungsbereinigte EBITDA-Marge steigt auf 28,4 % (Vorjahr: 26,9 %) Anteil margenstarker High Value Solutions (HVS) bei 57 % (Vorjahr: 55 %) Prognose für 2026: Währungsbereinigtes Umsatzwachstum von 2–5 % und EBITDA-M......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharmas vorläufige Ergebnisse für das Geschäftsjahr 2025; Ausblick für das Geschäftsjahr 2026 und aktualisierte Mittelfristprognose
Article
News Preview
SCHOTT Pharmas vorläufige Ergebnisse für das Geschäftsjahr 2025; Ausblick für das Geschäftsjahr 2026 und aktualisierte Mittelfristprognose Vorläufige Ergebnisse für das Geschäftsjahr 2025 entsprechen der Prognose: Umsatz von 986,2 Mio. Euro (währungsbereinigtes Wachstum von 5,8 %) EBITDA-Marge steigt auf 28,4 % (Vorjahr: 26,9 %) währungsberein......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
04.12.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Ausblick für das Geschäftsjahr 2026 und Aktualisierung der mittelfristigen Prognose
Article
News Preview
SCHOTT Pharma: Ausblick für das Geschäftsjahr 2026 und Aktualisierung der mittelfristigen Prognose Für das Geschäftsjahr 2026 erwartet SCHOTT Pharma ein währungsbereinigtes Umsatzwachstum im Bereich von 2-5% sowie eine EBITDA-Marge von rund 27%. Diese Prognose weicht von den aktuellen Markterwartungen von 8,2% währungsbereinigtem Wachstum und einer......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
04.12.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Outlook for fiscal year 2026 and update of mid-term guidance
Article
News Preview
SCHOTT Pharma: Outlook for fiscal year 2026 and update of mid-term guidance Today, SCHOTT Pharma issues its financial guidance for fiscal year 2026: The company expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%. This projection deviates from current market expectations (source: Vara consensus as o......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Christian Mias wird Nachfolger von Andreas Reisse als CEO von SCHOTT Pharma
Article
News Preview
SCHOTT Pharma: Christian Mias wird Nachfolger von Andreas Reisse als CEO von SCHOTT Pharma Andreas Reisse tritt wie geplant als CEO von SCHOTT Pharma in den Ruhestand Christian Mias, derzeit Executive Vice President der Business Unit Electronic Packaging bei SCHOTT, wird zum 1. Mai 2026 zum neuen CEO von SCHOTT Pharma ernannt Eine nahtlose Überg......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
 Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma
Article
News Preview
SCHOTT Pharma: Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Andreas Reisse to retire as CEO of SCHOTT Pharma as planned Christian Mias, Executive Vice President of SCHOTT’s Electronic Packaging Business Unit, appointed as new CEO of SCHOTT Pharma effective May 1st, 2026 Seamless leadership transition ensured The Supervisory ......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Christian Mias to succeed Andreas Reisse as CEO
Article
News Preview
The Supervisory Board of SCHOTT Pharma Management AG has today appointed Christian Mias as the new Chief Executive Officer (CEO) of SCHOTT Pharma, effective May 1, 2026. He will succeed Andreas Reisse, who will retire as planned at the end of April 2026. Christian Mias has held various management positions within the SCHOTT Group since 2007, most r......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Christian Mias wird Nachfolger von Andreas Reisse als CEO
Article
News Preview
Der Aufsichtsrat der SCHOTT Pharma Management AG hat heute Dr. Christian Mias mit Wirkung zum 1. Mai 2026 zum neuen Chief Executive Officer (CEO) von SCHOTT Pharma bestellt. Er folgt auf Andreas Reisse, der planmäßig Ende April 2026 in den Ruhestand gehen wird. Dr. Christian Mias ist seit 2007 in verschiedenen Führungspositionen innerhalb der SCHOT......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.08.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma delivers solid final third-quarter results
Article
News Preview
SCHOTT Pharma delivers solid final third-quarter results Q3 2025 revenues up 1% yoy to EUR 256m; increase of 3% yoy at constant currencies Q3 2025 EBITDA margin of 32.4% as reported and 31.7% at constant currencies Share of strong-margin high-value solutions (HVS) at 60% in Q3 2025 Organic revenue growth for FY 2025 is expected to be around 6.......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.08.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma erzielt solide finale Ergebnisse im dritten Quartal
Article
News Preview
SCHOTT Pharma erzielt solide finale Ergebnisse im dritten Quartal Umsatz in Q3 2025 um 1 % auf 256 Mio. Euro gestiegen; währungsbereinigtes Wachstum von 3 % gegenüber dem Vorjahr EBITDA-Marge in Q3 2025 berichtet bei 32,4 % und währungsbereinigt bei 31,7 % Anteil margenstarker High-Value-Lösungen (HVS) in Q3 2025 bei 60 % Prognose für organisch......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
Article
News Preview
SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance Q3 2025 revenues up 3% yoy at constant currencies to EUR 256m Q3 2025 EBITDA up 11% yoy to EUR 83m, with a quarterly margin of 32.4% (31.7% at constant currencies) Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management e......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
05.08.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma veröffentlicht vorläufiges Ergebnis für das dritte Quartal 2025 und präzisiert Prognose für das Geschäftsjahr 2025
Article
News Preview
SCHOTT Pharma veröffentlicht vorläufiges Ergebnis für das dritte Quartal 2025 und präzisiert Prognose für das Geschäftsjahr 2025 Umsatz in Q3 2025 steigt währungsbereinigt um 3 % auf 256 Mio. Euro EBITDA wächst in Q3 2025 um 11 % auf 83 Mio. Euro, die EBITDA Marge beträgt 32,4 % (31,7 % währungsbereinigt) Das organische Wachstum für das Geschäft......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
Article
News Preview
SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin SCHOTT Pharma specifies FY 2025 guidance: Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management expectations between 6.0% and 9.0% (“high-single digit”). The EBITDA margin for FY 2025 is expected to be around 28.0%, above the p......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma präzisiert die Prognose für Umsatzwachstum und EBITDA-Marge für das Geschäftsjahr 2025
Article
News Preview
SCHOTT Pharma präzisiert die Prognose für Umsatzwachstum und EBITDA-Marge für das Geschäftsjahr 2025 SCHOTT Pharma präzisiert die Prognose für das Geschäftsjahr 2025: Das organische Wachstum für das Geschäftsjahr 2025 wird ungefähr 6,0 % betragen, was am unteren Ende der Management-Erwartung von 6,0 % bis 9,0 % liegt („im hohen einstelligen Bereic......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.06.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma Aufsichtsrat verlängert Vertrag von CEO Andreas Reisse und ernennt Reinhard Mayer zum neuen CFO
Article
News Preview
SCHOTT Pharma Aufsichtsrat verlängert Vertrag von CEO Andreas Reisse und ernennt Reinhard Mayer zum neuen CFO Der Vertrag von SCHOTT Pharma CEO Andreas Reisse wird verlängert CFO Dr. Almuth Steinkühler verlässt das Unternehmen auf eigenen Wunsch, um sich neuen beruflichen Herausforderungen zu widmen Reinhard Mayer wird CFO von SCHOTT Pharma Der......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.06.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO
Article
News Preview
SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO Andreas Reisse’s contract as CEO of SCHOTT Pharma extended CFO Dr. Almuth Steinkühler to leave the company at her own request to pursue new professional opportunities Reinhard Mayer appointed as new CFO of SCHOTT Pharma The Supervisory B......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.06.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma investiert in die Produktion steriler Karpulen in Ungarn
Article
News Preview
SCHOTT Pharma investiert in die Produktion steriler Karpulen in Ungarn 4. Juni 2025, Lukácsháza, Ungarn SCHOTT Pharma beginnt mit dem Bau einer neuen Produktionsstätte für gebrauchsfertige Karpulen in Ungarn Die Investition von über 100 Millionen Euro ist Teil der Expansionsstrategie des Unternehmens, um der wachsenden Nachfrage nach High-Value-......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.06.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma invests in sterile cartridge production in Hungary
Article
News Preview
SCHOTT Pharma invests in sterile cartridge production in Hungary June 4, 2025, Hungary, Lukácsháza SCHOTT Pharma breaks ground for a new production facility for ready-to-use cartridges in Hungary Its investment of over EUR 100 million is part of the company’s expansion strategy to meet the growing market demand for high-value solutions The new ......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma schließt starkes zweites Quartal im Geschäftsjahr 2025 ab
Article
News Preview
SCHOTT Pharma schließt starkes zweites Quartal im Geschäftsjahr 2025 ab Umsatz in Q2 2025 um 8 % auf 252 Mio. Euro gestiegen; währungsbereinigtes Wachstum von 10 % gegenüber dem Vorjahr EBITDA-Marge in Q2 2025 berichtet bei 28,6 % und währungsbereinigt bei 28,2 % Anteil margenstarker High-Value-Lösungen (HVS) in Q2 2025 bei 56 % SCHOTT Pharma b......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
Article
News Preview
SCHOTT Pharma delivers strong second quarter of fiscal year 2025 Q2 2025 revenues up 8% yoy to EUR 252m; increase of 10% yoy at constant currencies Q2 2025 EBITDA margin of 28.6% as reported and 28.2% at constant currencies Share of strong-margin high-value solutions (HVS) at 56% in Q2 2025 SCHOTT Pharma reaffirms FY 2025 guidance SCHOTT Pharma......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.05.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poonawalla
Article
News Preview
 SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poonawalla TPG, a leading global alternative asset management firm will acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India (SII)  SII will retain a minority stake in the company, with SCHOTT Pharma ......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.05.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma und Serum Institute of India begrüßen neuen Partner in Joint Venture in Indien; TPG investiert in SCHOTT Poonawalla
Article
News Preview
SCHOTT Pharma und Serum Institute of India begrüßen neuen Partner in Joint Venture in Indien; TPG investiert in SCHOTT Poonawalla TPG, eine weltweit führende alternative Investmentgesellschaft, übernimmt 35 % der Anteile an SCHOTT Poonawalla von Serum Institute of India (SII) SII wird weiterhin eine Minderheitsbeteiligung an dem Unternehmen halte......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma: Vorläufiges Q2 2025-Ergebnis liegt über den Markterwartungen
Article
News Preview
SCHOTT Pharma: Vorläufiges Q2 2025-Ergebnis liegt über den Markterwartungen   SCHOTT Pharma erwartet auf Basis vorläufiger Zahlen einen Anstieg bei Umsatz, EBITDA und EBITDA-Marge für das zweite Quartal 2025 (zum 31. März 2025). Das Unternehmen rechnet mit einem Umsatz in Höhe von 252 Mio. Euro und einem währungsbereinigten Wachstum von 10 %. Dami......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations 
Article
News Preview
SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations  Based on preliminary figures, SCHOTT Pharma expects an increase in sales, EBITDA and EBITDA margin in the second quarter of 2025 (as of March 31, 2025). The company expects Q2 2025 revenues of EUR 252m, corresponding to a year-over-year growth of 10% at constant currenc......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe
Article
News Preview
Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe April 10, 2025, Jagodina, Serbia After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia Production capacity to meet European mar......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma eröffnet Produktionsstätte in Serbien zur Stärkung der Wettbewerbsfähigkeit in Europa
Article
News Preview
Nächster Expansionsmeilenstein erreicht: SCHOTT Pharma eröffnet Produktionsstätte in Serbien zur Stärkung der Wettbewerbsfähigkeit in Europa April 10, 2025, Jagodina, Serbia Nach einer Investition im zweistelligen Millionenbereich und einer Bauzeit von weniger als eineinhalb Jahren eröffnet SCHOTT Pharma eine neue Produktionsstätte in Jagodina, S......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.02.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma startet gut ins neue Geschäftsjahr und bestätigt Prognose für 2025
Article
News Preview
SCHOTT Pharma startet gut ins neue Geschäftsjahr und bestätigt Prognose für 2025 Q1 2025: Umsatz von 230 Mio. Euro; berichteter Rückgang von 1 %, währungsbereinigtes Umsatzwachstum von 4 % gegenüber dem Vorjahr Q1 2025: EBITDA-Marge von 25,1 % berichtet, und 26,3 % währungsbereinigt Anteil der margenstarken High-Value-Lösungen (HVS) weiter auf ......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.02.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma records good start into fiscal year and confirms full year outlook
Article
News Preview
SCHOTT Pharma records good start into fiscal year and confirms full year outlook Q1 2025 revenues reached EUR 230m; decrease of 1% yoy as reported or increase of 4% at constant currencies Q1 2025 EBITDA margin of 25.1% as reported or 26.3% at constant currencies Share of strong-margin high-value solutions (HVS) further increased to 55% Busines......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.02.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma mit erfolgreicher Hauptversammlung – Aktionärinnen und Aktionäre stimmen allen Tagesordnungspunkten zu
Article
News Preview
SCHOTT Pharma mit erfolgreicher Hauptversammlung – Aktionärinnen und Aktionäre stimmen allen Tagesordnungspunkten zu SCHOTT Pharma hat am 4. Februar 2025 seine ordentliche Hauptversammlung virtuell abgehalten Aktionärinnen und Aktionäre stimmten allen Tagesordnungspunkten zu Dr. Wolfram Carius wurde als Nachfolger von Dr. Wolfgang Wienand in de......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.02.2025
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Shareholders approve all agenda items
Article
News Preview
SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items SCHOTT Pharma held its Annual General Meeting virtually on February 4, 2025 All items on the agenda were approved by shareholders Dr. Wolfram Carius has been appointed to SCHOTT Pharma’s Supervisory Board, replacing Dr. Wolfgang Wienand   SCHOTT Pharma, ......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma erreicht starkes Wachstum und Rekordmarge nach gutem Jahresendspurt
Article
News Preview
SCHOTT Pharma erreicht starkes Wachstum und Rekordmarge nach gutem Jahresendspurt Alle Ziele für 2024 erreicht, einschließlich angehobener Umsatzprognose: 12 % Umsatzwachstum und EBITDA-Marge von 27,8 %, beides währungsbereinigt Q4 2024 Umsatz bei 237 Mio. Euro; EBITDA-Marge von 27,9 % deutlich über dem Vorjahr Umsatz für Geschäftsjahr 2024 bei......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.12.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma with strong growth and record margin after solid year-end finish
Article
News Preview
SCHOTT Pharma with strong growth and record margin after solid year-end finish All 2024 targets met including raised revenue guidance: 12% revenue growth and EBITDA margin of 27.8%, both at constant currencies Q4 2024 revenues reached EUR 237m; EBITDA margin of 27.9% well above prior year FY 2024 revenues reached EUR 957m; EBITDA margin of 26.9......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma präsentiert innovatives Nestdesign für vorsterilisierte Karpulen
Article
News Preview
Effizient und nachhaltig: SCHOTT Pharma präsentiert innovatives Nestdesign für vorsterilisierte Karpulen Neues rautenförmiges Nest für vorsterilisierte, ready-to-use (RTU)-Karpulen steigert die Effizienz von pharmazeutischen Abfüllprozessen um bis zu 67% und reduziert die CO2-Emissionen in der Lieferkette um beinahe 25% für 1,5 ml Karpulen. Je na......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges
Article
News Preview
Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the supply chain for 1.5 ml RTU cartridges......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”
Article
News Preview
SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU” Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical manufacturing processes Increased patient safety with high-quality sterile primary packaging SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), a pioneer ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.09.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma, Gerresheimer und Stevanato Group schließen strategische 'Allianz für RTU'
Article
News Preview
SCHOTT Pharma, Gerresheimer und Stevanato Group schließen strategische "Allianz für RTU" Marktakzeptanz von „Ready-to-Use“-Primärverpackungen schreitet voran Verbesserung der Betriebseffizienz in pharmazeutischen Herstellungsprozessen Erhöhung der Patientensicherheit durch hochwertige sterile Primärverpackungen SCHOTT Pharma AG & Co. KGaA (M......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.09.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Listed on the MDAX for the first time
Article
News Preview
Promotion for SCHOTT Pharma: Listed on the MDAX for the first time SCHOTT Pharma to join the 90 most important shares listed on the Frankfurt stock exchange as of September 23, 2024 MDAX promotion proves confidence in the company’s business model, strategic focus and ideal market position   The shares of SCHOTT Pharma AG & Co. KGaA, a global......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.09.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
Erstmalige Aufnahme in den MDAX
Article
News Preview
Aufstieg für SCHOTT Pharma: Erstmalige Aufnahme in den MDAX SCHOTT Pharma gehört ab dem 23. September 2024 zu den 90 wichtigsten Aktien an der Frankfurter Wertpapierbörse MDAX-Aufstieg belegt Vertrauen in das Geschäftsmodell, die strategische Ausrichtung und die optimale Marktposition des Unternehmens Die Aktien der SCHOTT Pharma AG & Co. KGa......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance 
Article
News Preview
SCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance  Q3 2024 revenues up 21% yoy to EUR 268m at constant currencies Strong Q3 2024 EBITDA margin of 28.2% at constant currencies Share of strong-margin high-value solutions (HVS) at 53% in the first nine month of FY 2024 SCHOTT Pharma increases revenue guidance ......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma erzielt starke Ergebnisse im dritten Quartal und erhöht Umsatzprognose für das Geschäftsjahr 2024
Article
News Preview
SCHOTT Pharma erzielt starke Ergebnisse im dritten Quartal und erhöht Umsatzprognose für das Geschäftsjahr 2024 Q3 2024 Umsatzerlöse steigen währungsbereinigt um 21 % gegenüber Vorjahr auf 268 Mio. Euro Starke Q3 2024 währungsbereinigte EBITDA-Marge von 28,2 % Umsatzanteil der margenstarken High-Value-Lösungen (HVS) bei 53 % in den ersten neun ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma richtet Klimaschutzmaßnahmen an den Anforderungen des Pariser Abkommens aus
Article
News Preview
 SCHOTT Pharma richtet Klimaschutzmaßnahmen an den Anforderungen des Pariser Abkommens aus 8. August 2024, Deutschland, Mainz SCHOTT Pharma bekennt sich zu seiner Verantwortung, Emissionen zu reduzieren, um die globale Erwärmung auf 1,5°C zu begrenzen. Die unabhängige Science Based Targets Initiative (SBTi) hat die Klimaschutz-Roadmap und Ziele ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
 SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement
Article
News Preview
SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement August 8, 2024, Germany, Mainz SCHOTT Pharma is fully committed to take responsibility for emission reduction to support limitation of global warming to 1.5°C. The independent Science Based Targets initiative (SBTi) has validated the clima......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.07.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma introduces nest design with more cavities for prefillable polymer syringes
Article
News Preview
Transforming operational efficiency and sustainability: SCHOTT Pharma introduces nest design with more cavities for prefillable polymer syringes 31 July 2024, Germany, Mainz SCHOTT Pharma’s new nest holds 160 prefillable polymer syringes, which marks an increase of 60 syringes per nest. The new nest design allows pharma companies to increase the......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.07.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma führt neues Nestdesign mit erhöhter Anzahl an vorfüllbaren Polymerspritzen ein
Article
News Preview
Effizient und nachhaltig: SCHOTT Pharma führt neues Nestdesign mit erhöhter Anzahl an vorfüllbaren Polymerspritzen ein 31. Juli 2024, Deutschland, Mainz Neues Nest von SCHOTT Pharma bietet bei gleichbleibenden Außenmaßen Platz für 160 anstelle von 100 vorfüllbare Polymerspritzen Dank verändertem Design können Pharmaunternehmen ihre Effizienz um ......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma bringt vorsterilisierte großvolumige Karpulen für tragbare Injektoren auf den Markt
Article
News Preview
Subkutane Selbstmedikation fördern: SCHOTT Pharma bringt vorsterilisierte großvolumige Karpulen für tragbare Injektoren auf den Markt 16. Juli 2024, Deutschland, Mainz Die neuen vorsterilisierten 10 ml-Karpulen von SCHOTT Pharma eignen sich insbesondere zur Aufbewahrung hochsensibler Biologika, die u.a. zur Behandlung von Krebs, Stoffwechselstöru......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.07.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices
Article
News Preview
Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices 16 July 2024, Germany, Mainz SCHOTT Pharma introduces new 10ml ready-to-use (RTU) cartridges, specifically designed to store highly sensitive biologics used to treat cancer, metabolic disorders, cardiovascular......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma setzt Wachstumskurs im zweiten Quartal des Geschäftsjahres 2024 fort
Article
News Preview
SCHOTT Pharma setzt Wachstumskurs im zweiten Quartal des Geschäftsjahres 2024 fort Q2 2024 Umsatzerlöse steigen währungsbereinigt um 11 % gegenüber Vorjahr auf 247 Mio. Euro Q2 2024 währungsbereinigte EBITDA-Marge von 27,0 % Umsatzanteil der margenstarken High-Value-Lösungen (HVS) bei 53 % in der ersten Hälfte des Geschäftsjahres 2024 Prognose......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Article
News Preview
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024 Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies Q2 2024 EBITDA margin of 27.0% at constant currencies Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024 Guidance for fiscal year 2024 confirmed SCHOTT Pharma, a pioneer ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Article
News Preview
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024 Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies Q2 2024 EBITDA margin of 27.0% at constant currencies Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024 Guidance for fiscal year 2024 confirmed SCHOTT Pharma, a pioneer ......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma eröffnet hochmoderne Produktionsstätte im ungarischen Lukácsháza
Article
News Preview
Erweiterung der Produktion von vorfüllbaren Glasspritzen: SCHOTT Pharma eröffnet hochmoderne Produktionsstätte im ungarischen Lukácsháza   11. Juni 2024, Lukácsháza, Ungarn Nach einer Investition von 76 Millionen Euro (28,044 Milliarden HUF) und eineinhalb Jahren Bauzeit eröffnet SCHOTT Pharma seine neueste Produktionsstätte in Lukácsháza, Unga......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.06.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary
Article
News Preview
Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary June 11, 2024, Lukácsháza, Hungary After EUR 76 million (HUF 28,044 billion) investment and 1.5 years of construction, SCHOTT Pharma opens its newest production facility in Lukácsháza, Hungary Expanding production capacity ......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
Article
News Preview
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes H1 24 revenues up 9% yoy at constant currencies to EUR 489m; EBITDA margin of 27.4% at constant currencies FY 25 revenue growth projections impacted by lower demand for syringes from one customer Mid-term outlook confirmed Full set of Q2......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma bestätigt Prognose für das Geschäftsjahr 2024 anlässlich seiner Q2-Ergebnisse; Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst
Article
News Preview
SCHOTT Pharma bestätigt Prognose für das Geschäftsjahr 2024 anlässlich seiner Q2-Ergebnisse; Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst H1 24 Umsatzerlöse steigen währungsbereinigt um 9 % gegenüber Vorjahr auf 489 Mio. Euro; währungsbereinigte EBITDA-Marge von 27,4 % Prognose für Umsatzwachstum für das Geschäftsjahr 20......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma see FY 25 impacted by slower growth from syringes
Article
News Preview
SCHOTT Pharma see FY 25 impacted by slower growth from syringes For its fiscal year 2024/2025, beginning 1st October 2024, the company is forecasting a revenue growth in a high single-digit to a low double-digit percentage range, which deviates from the current market consensus. Due to the revenue growth that is lower than previously expected, the......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma sieht Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst
Article
News Preview
SCHOTT Pharma sieht Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst Die Gesellschaft prognostiziert gegenwärtig für ihr am 1. Oktober 2024 beginnendes Geschäftsjahr 2024/2025 abweichend von der vorherrschenden Markterwartung ein Umsatzwachstum in der Bandbreite eines hohen einstelligen bis niedrigen zweistelligen Prozentsatze......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma sieht Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst
Article
News Preview
SCHOTT Pharma sieht Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst Die Gesellschaft prognostiziert gegenwärtig für ihr am 1. Oktober 2024 beginnendes Geschäftsjahr 2024/2025 abweichend von der vorherrschenden Markterwartung ein Umsatzwachstum in der Bandbreite eines hohen einstelligen bis niedrigen zweistelligen Prozentsatze......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.04.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations
Article
News Preview
SCHOTT Pharma appoints Tobias Erfurth as Head of Investor Relations Tobias Erfurth will lead Investor Relations Team starting in August 2024. He brings more than 20 years of experience in finance, capital markets and investor relations. SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today announced the appoint......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.04.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations
Article
News Preview
SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations Tobias Erfurth übernimmt Leitung des Investor Relations-Teams ab Mitte August 2024 Er verfügt über mehr als 20 Jahre Erfahrung im Finanz- und Kapitalmarktsektor sowie im Bereich Investor Relations SCHOTT Pharma, ein Pionier für pharmazeutische Aufbewahrungs- und Verabreichungssyst......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.04.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations
Article
News Preview
SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations Tobias Erfurth übernimmt Leitung des Investor Relations-Teams ab Mitte August 2024 Er verfügt über mehr als 20 Jahre Erfahrung im Finanz- und Kapitalmarktsektor sowie im Bereich Investor Relations SCHOTT Pharma, ein Pionier für pharmazeutische Aufbewahrungs- und Verabreichungssyst......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 12.12.2025, Calendar Week 50, 346th day of the year, 19 days remaining until EoY.